For Primary Antibodies click here
For Full IHC Range click here
PRAME - CE IVD
Preferentially expressed antigen in melanoma (PRAME) is a tumour-associated antigen that is preferentially expressed in human melanomas recognised by Cytolytic T Lymphocytes. Normal tissues show low or no
expression (except testis, ovary, placenta, adrenals and endometrium), therefore it is called a member of the family of cancer testis antigens.
PRAME is also expressed in malignant cells, including leukaemias, Hodgkin's lymphoma and breast cancer.
This antibody can be used as a melanoma marker to differentiate between benign and malignant tumours.
PAX- 8 - IVD
PAX-8 is a member of the paired box (PAX) family of transcription factors, expressed during foetal development. It is essential for organogenesis during the embryonic development of kidney, Müllerian pipe organ and thyroid. Transcription factors often disappear in mature tissues, but they may re-express in an organ-specific manner during neoplastic transformation.
Due to the restrictive expression in normal tissues, PAX8 is a sensitive and specific marker for primary tumours as well as for metastatic tumours derived from the above-mentioned organs and tissues. It has been reported that PAX8 is widely expressed in various types of ovarian tumours, particularly in serous tumours such as ovarian endometrioid carcinoma and clear cell carcinoma.
Recently the research of Programmed Death Ligand 1 (PD-L1, also known as CD274 or B7-H1) has become more
attractive because of its role in cancer therapy. The 40 kDa transmembrane protein binds to the PDL1 receptor which is
a T cell immune checkpoint. The activation of the pathway leads to an inhibition of the T cell activation to avoid an
autoimmune response. Several tumour cell and tumour-infiltrating immune cells exploit this mechanism to evade
destruction and to be resistant to CD8+ T cell mediated lysis.
AnatoPath offers PD-L1 (clone QR1) monoclonal rabbit antibody that is reactive in formalin-fixed paraffin-embedded human tissues. The antibody is a predictive marker of different cancer types, including sentinel lymph node melanoma, renal cell carcinoma, non-small cell lung cancer and triple negative breast cancer cells where it provides a membranous and cytoplasmic staining.